Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Trial Profile

A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs RG 7880 (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 01 Feb 2019 Planned End Date changed from 6 Jul 2022 to 17 Dec 2022.
    • 01 Feb 2019 Planned primary completion date changed from 6 Jul 2022 to 17 Dec 2022.
    • 04 Jan 2019 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top